13FGuru
Sign in with Google Sign in with Discord

NASDAQ · Health Care

HALOZYME THERAPEUTICS INC HALO

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Sources StockAnalysis company profile stockanalysis.com
Biotechnology: Biological Products (No Diagnostic Substances)

Company profile

Business mix

  • The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
  • It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents.
  • The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis.
  • It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within biotechnology?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 2 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 25.18 FCF 7.87% Buyback 4.58%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Gotham Asset Management Joel Greenblatt 0.1% $48.3M 2026-03-31
Bridgewater Associates Ray Dalio 0.1% $33.1M 2026-03-31

Recent trading changes over the last 4 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 2 Last 4 13F filing periods
Net reducers 0 Last 4 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $65.0M Estimated from net added shares
Reduction amount $0 Estimated from net reduced shares
Net share change / base shares +397.5% +1,005,336 / 252,934
Bridgewater Associates Ray Dalio 3 filing periods
13F 2025-09-30 Filed 2025-11-13
New Shares - 13F value change +$35.7M
13F 2025-12-31 Filed 2026-02-13
Major increase Shares 15.3% 13F value change +$2.1M
13F 2026-03-31 Filed 2026-05-15
Minor reduction Shares -8.9% 13F value change -$4.7M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 0 Last 4 periods +511,429 (New) Total shares 511,429 Value $33.1M
Gotham Asset Management Joel Greenblatt 2 filing periods
13F 2025-12-31 Filed 2026-02-17
Major increase Shares 73.8% 13F value change +$11.0M
13F 2026-03-31 Filed 2026-05-15
Major increase Shares 69.8% 13F value change +$18.7M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 252,934 Last 4 periods +493,907 (+195.3%) Total shares 746,841 Value $48.3M

Recent mentions

No public mentions.